DOCSLIB.ORG

ANNUAL REPORT 2012 Contents OUR Mission

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ANNUAL REPORT 2012 Contents OUR Mission ANNUAL REPORT 2012 cONTENTs OUR missiON GROUP REviEW Financial Highlights 2 We want to discover, develop and News in 2012 3 successfully market innovative Letter from Daniel vasella 5 products to prevent and cure interview with Joseph Jimenez 11 diseases, to ease suffering and HEALTHcAREPORTFOLiO contents 17 to enhance the quality of life. Pharmaceuticals 21 Novartis institutes for Biomedical Research 33 We also want to provide a Alcon 37 shareholder return that reflects sandoz 47 outstanding performance and vaccines and Diagnostics 53 to adequately reward those consumer Health 59 who invest ideas and work in cORPORATE REsPONsiBiLiTy contents 65 our company. Expanding Access to Healthcare 67 Doing Business Responsibly 77 independent Assurance Report 85 cORPORATE GOvERNANcE contents 87 Our Board of Directors 96 Our management 110 cOmPENsATiON REPORT contents 121 compensation Report 122 NOvARTis GROUP FiNANciAL REPORT contents 147 Financial Highlights 2012 148 Key Financial Developments 149 Operating and Financial Review 150 shareinformation 168 summary of Key Financial Data 188 Novartis Group consolidated Financial statements 190 Financial statements of Novartis AG 258 Annual Report Photography and Films 278 Key Dates 2013, contact information 280 and Forward-Looking statements 1 GROUP REviEW Novartis provides healthcare solutions that address the evolving needs of patients and societies worldwide. Our portfolio focuses on broad areas of healthcare: pharmaceuticals, eye care, generics, vaccines, consumer-based OTc and animal health. FiNaNcial hiGhliGhts KEY FIGURES NET SALES, OPERATING INCOME, NET INCOME, CORE OPERATING (in USD millions, unless indicated otherwise) INCOME AND CORE NET INCOME (Index: 2008 = 100%) 2012 2011 160 Net sales 56 673 58 566 150 Operating income 11 511 10 998 Return on net sales (%) 20.3 18.8 140 Net income 9618 9245 130 Basic earnings per share 1 (USD) 3.93 3.83 Core operating income 2 15 160 15 909 120 Core return on net sales (%) 26.7 27.2 110 Core net income 2 12 811 13 490 100 Core earnings per share 1,2 (USD) 5.25 5.57 Core Research & Development 2 9116 9239 90 As a % of net sales 16.1 15.8 2008 2009 2010 2011 2012 Number of associates (FTE) 3 127 724 123 686 Group free cash flow 11 383 12 503 Net sales Core operating income Operating income Core net income Net income SHARE INFORMATION 2012 NET SALES BY REGION (% and in USD millions) 2012 2011 Share price at year end (CHF) 57.45 53.70 United States 33 18 592 ADS price at year end (USD) 63.30 57.17 Europe 35 19 708 Dividend 4 (CHF) 2.30 2.25 Payout ratio 5 65 66 Asia/Africa/Australasia 23 12 936 Canada and Latin America 9 5437 Total 56 673 1 2012 average number of shares outstanding: 2418.1 million (2011: 2382.5 million). 4 Dividend payment for 2012: proposal to 2013 Annual General Meeting. 2 Core results for operating income, net income, earnings per share (EPS) and R&D eliminate the 5 Payout ratio is calculated by converting into USD the proposed total gross dividend amount in impact of acquisition-related factors and other significant exceptional items. These adjustments CHF at the CHF-USD exchange rate of December 31, 2012 based on an estimated number of are explained in detail starting on page 182. shares outstanding on dividend payment date and dividing it by the USD consolidated net 3 Full-time equivalent positions at year end. income attributable to shareholders of Novartis AG based on the Novartis Group’s 2012 consolidated financial statements. 2 Novartis Group aNNual report 2012 News iN 2012 PERFORmANcE Net sales were UsD 56.7 billion, down 3% (unchanged in constant currencies, or cc) from the previous year. Operating income grew 5% (+8% cc) to UsD 11.5 billion. core operating income declined 5% (–2% cc) to UsD 15.2 billion. core operating income margin decreased by 0.5 percentage points to 26.7% of net sales. PRODUcTs Recently launched products accounted for UsD 16.3 billion or 29% of Group net sales, up from 25% in 2011. continuing to rejuvenate the portfolio, Pharmaceuticals achieved 11 major regulatory approvals for innovative medicines and new indications in the United states and the European Union. Key approvals included Afinitor in the United states and the European Union in advanced breast cancer, Jakavi in the European Union in myelofibrosis, and Seebri Breezhaler in the European Union for patients with chronic obstructive pulmonary disease (cOPD). Alcon also received FDA approval for Dailies Total1, the industry’s first water-gradient silicone hydrogel contact lens. in vaccines and Diagnostics, Flucelvax, the first cell-culture vaccine in the United states to help pro- tect against seasonal influenza, received FDA approval, and BexserO secured a positive cHmP opinion for use preventing meningococcal serogroup B infections in individuals 2 months of age and older. PiPELiNE Novartis has a leading new product pipeline with more than 200 projects in clinical development, including 138 in the Pharmaceuticals Division. in pipeline highlights, the first five studies in the QvA149 Phase iiiiGNiTE clinical trial program all met their primary endpoints and showed that QvA149 significantly improved lung function compared with other cOPD therapies. Results from a Phase iii study showed that investigational com- pound RLX030 reduces the mortality rate in patients with acute heart failure. Alcon has leveraged the capabilities of the Novartis institutes for Biomedical Research to gain access to a range of technologies and has prioritized glaucoma and macular degeneration in drug discovery efforts. sandoz initiated a Phase iii clinical trial for epoetin alfa in the United states, and continued to progress the follicular lymphoma Phase iii clinical trial forbiosimilar monoclonal antibody rituximab. Thevaccines and Diagnostics pipeline continues to focus on meningococcal disease and influenza. REsEARcH AND DEvELOPmENT Reflecting our commitment to innovation, we invested 21% of Pharmaceuticals net sales in R&D, focusing on the areas of greatest patient need and scientific promise. PORTFOLiO We continued to strengthen our broad, diversified healthcare portfolio with the acquisition of Fougera Pharmaceuticals inc. by our sandoz Division, making it the number one generic dermatology medicines company in the United states and globally. cORPORATE REsPONsiBiLiTy Engaging with society to improve access to healthcare is integral to the way Novartis oper- ates. in 2012, our contributions and programs in this area were valued at UsD 2 billion, providing medicine to more than 100 million patients, and health education, infrastructure development and other programs to another 7. 2 million people worldwide. DiviDEND We propose to deliver our 16th consecutive dividend increase, with a 2% raise proposed for 2012 to cHF 2.30 per share (2011: cHF 2.25 per share), a dividend yield of 4.0%. 2|Group review 17 |HEALTHcARE PORTFOLiO65|cORPORATEREsPONsiBiLiTy 87 | cORPORATEGOvERNANcE 121|cOmPENsATiON REPORT 147|FiNANciALREPORT 3 Financial Highlights | News in 2012 forced to deal with increased price pressure, the patent expiration for our successful heart drug Diovan, and persistent turbulence on financial and currency markets. moreover, quality problems at sandoz andconsumer Health led to production downtime, which also affected results. Despite these far-reaching events, Novartis was able to provide 1.2 billion patients world- wide with medical care in 2012 –exceeding the record-setting level of previous years – thanks to recently launched products and the further expansion in fast-growing markets. The Group’s net sales reached UsD 56.7 bil- Daniel vasella, m.D. lion (–3%, unchanged in constant curren- cies), while net income increased by 4% (7% in constant currencies) to UsD 9.6 billion. DEAR sHAREHOLDER The pharmaceuticals Division (UsD 32.2 bil- the economic and debt crisis has cast a lion, 2% in constant currencies) rejuvenated shadow over europe and the united states its product portfolio with the help of recently for more than four years, and it significantly launched products such as leukemia drug affected 2012, as well. Despite major con- Tasigna and ophthalmic medicine Lucentis, certed efforts, the end of this troubling which helped balance the Diovan patent loss. period is not yet in sight. moreover, groundbreaking therapies such as Gilenya and Afinitor – which in 2012 Even the regions and markets that have so posted revenue growth in constant curren- far escaped the crisis are now in danger of cies of 147% and 85%, respectively –are being affected by its socioeconomic side expected to generate sustainable growth in effects. Protectionist market interventions, the future. monetary expansionand over-regulation – all signs of reactive politics – are increasing alcon (UsD 10.2 billion, 5% in constant cur- and can lead to a deepening of structural rencies) was able to assert itself and with- deficits. Persistent weak growth is likely, stand the growing price pressure and com- despite low interest rates and monetary ex- petition from generics, due to product pansion. High levels of public debt make the launches and the successful integration of problem worse in many countries, and there ciBA vision. sandoz (UsD 8.7 billion, –4% in is no certainty as to whether pension funds constant currencies) succeeded in com- and social welfare institutions will be able to pensatingfor the competition-drivenprice meet their promises in the medium term. decline of enoxaparin, on the back of strong demand for biosimilars, growth in emerging despite this ominous backdrop, Novartis once markets, and the strategically significant again posted strong results in 2012. This is acquisition of Us dermatology drug maker all the more remarkable given that we were Fougera. 2|Group review 17 |HEALTHcARE PORTFOLiO65|cORPORATEREsPONsiBiLiTy 87 | cORPORATEGOvERNANcE 121|cOmPENsATiON REPORT 147|FiNANciALREPORT 5 Letter from Daniel vasella The performance of otcand animal health, research and development, distribution, which together make up consumer health and production allows us to benefit from the (UsD 3.7 billion, –16% in constant currencies), advantages of our Group structure.
Load more

Recommended publications
  • Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi
    Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research Leading biopharmaceutical organizations join Project Baseline initiative to engage more patients and clinicians in research and speed evidence generation South San Francisco, CA -- May 21, 2019 -- Verily, an Alphabet company, today announced strategic alliances with Novartis (NYSE: NVS), Otsuka (NYSE: OTSKY), Pfizer Inc. (NYSE: PFE) and Sanofi (EURONEXT: SAN, NASDAQ: SNY) to develop digitally innovative, patient-centered clinical research programs using Project Baseline’s evidence generation platform and tools. The Baseline Platform is designed to engage more patients and clinicians in research, increase the speed and ease of conducting studies and collect more comprehensive, higher quality data, including outside the four walls of a clinic. Across the United States, the number of people participating in clinical research -- including clinical trials and observational studies -- is less than 10% of the population.1 In addition to low participation, challenges in research include data fragmentation, inefficient operations and limited value for patients. Alongside academic research institutions, patient-advocacy groups and health systems, Verily and its industry partners aim to implement a more patient-centric, technology-enabled approach to research, and increase the number and diversity of clinical research participants. They will also explore novel approaches to generating real-world evidence using the Baseline Platform to collect, organize and activate health information from electronic health records, sensors and other digital sources. Over the coming years, Novartis, Otsuka, Pfizer and Sanofi each plan to launch clinical studies leveraging the platform across diverse therapeutic areas, such as cardiovascular disease, oncology, mental health, dermatology and diabetes.
    [Show full text]
  • 312.1.Full.Pdf
    Ann Rheum Dis: first published as 10.1136/annrheumdis-2021-eular.1066 on 19 May 2021. Downloaded from 312 Scientific Abstracts Acknowledgements: This study was funded by Novartis Pharma AG. The found many DEGs from baseline with GUS treatment and none with PBO. These authors thank Richard Karpowicz, PhD, of Health Interactions, Inc, for providing included genes related to B-, T-, NK-, and plasma cells (increased by GUS) and medical writing support/editorial support, which was funded by Novartis Pharma- neutrophils, monocytes, eosinophils, and macrophages (decreased by GUS), ceuticals Corporation, East Hanover, NJ, in accordance with Good Publication suggestive of a partial normalization of immune cell composition in whole blood. Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). Conclusion: Using whole transcriptome profiling, we detected DEGs in blood Disclosure of Interests: Gurjit S. Kaeley Consultant of: Novartis Pharmaceuti- samples obtained from PsA pts vs. healthy controls, suggesting a dysregulation cals Corporation, Georg Schett Speakers bureau: AbbVie, Bristol Myers Squibb, of immune cell profiles in PsA. The majority of these disease-associated genes Celgene, Janssen, Eli Lilly, Novartis, and Pfizer, Consultant of: AbbVie, Bristol were modulated by GUS, with directionality toward a normalization of whole Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, and UCB, Grant/research blood transcriptomic signatures. support from: Bristol Myers Squibb, Celgene, GSK, Eli Lilly, and Novartis, Philip REFERENCES: G Conaghan Consultant of: or Speakers bureau: AbbVie, AstraZeneca, Bristol [1] Deodhar A et al. Lancet. 2020;395:1115. Myers Squibb, Eli Lilly, EMD Serono, Flexion Therapeutics, Galapagos, Gilead, [2] Mease P et al. Lancet. 2020;395:1126. Novartis, and Pfizer, Grant/research support from: UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Dennis McGona- Table 1.
    [Show full text]
  • CA Signed Novartis 315 Settlement Agreement Signed California
    STATE SETTLEMENT AGREEMENT I. PARTIES This Settlement Agreement (the "Agreement") is entered into between the State of California ("the State") and Novartis Pharmaceuticals Corporation ("Novartis"), collectively, "the Parties." II. PREAMBLE As a preamble to this Agreement, the Parties agree to the following: A. At all relevant times, Novartis, (a subsidiary of Novartis International AG, which is headquartered in Basel, Switzerland) was a corporation with its principal place of business in East Hanover, New Jersey, distributed, marketed and/or sold pharmaceutical products in the United States, including drugs sold under the trade names of Lotrel, Valturna, Starlix, Tekamlo, Diovan, Diovan HCT, Tekturna, Tekturna HCT, Exforge, and Exforge HCT (the "Covered Drugs"). B. On January 5, 2011 , Oswald Bilotta, (the "Relater") filed a sealed qui tam action, which was subsequently amended on October 19, 2012, as of right on April 3, 2013 (pursuant to an unopposed motion dated March 21 , 2013), and on July 10, 2013 (pursuant to a stipulation dated July 8, 2013) (the "Civil Action") in the United States District Court for the Southern District of New York captioned United States of America et al. , ex rel. Oswald Bilotta et al. v. Novartis Pharmaceuticals Corporation Civil Action No. 1 l-cv-00071 , alleging, inter alia, that Novartis violated the False Claims Act ("FCA") and the Anti-Kickback Statute, 42 U.S.C. §I320a-7b(b) (the "AKS"), by paying doctors remuneration to prescribe the drugs Lotrel, Valturna, Starlix, Tekturna, Tekturna HCT, Diovan, Diovan HCT, Exforge, and Exforge HCT through the mechanism ofspeaker program honoraria and related misconduct. Novartis-315 Page 1 of 19 On April 26, 2013, the United States intervened in the Civil Action against Novartis by filing a Notice of Election to Intervene and Complaint-in-Intervention, in which it is asserted that claims against Novartis under the FCA and common law.
    [Show full text]
  • Event Calendar
    Published on Novartis (https://www.novartis.com) Home > Printer-friendly PDF > Event Calendar Event Calendar View recent presentations and learn more about upcoming events. Disclaimer: Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates. Tab: Upcoming Events Third quarter results 2021 Oct 26, 2021 Basel, Switzerland Recent Events [1] ESG Investor Day Sep 30, 2021 Watch the webcast [2] Download the podcast (MP3 66 MB) [3] Access our interactive slide deck (PDF 9.6 MB) [4] Read the media release [5] Novartis ESG Investor Day 2021 6 key takeaways [6] Bernstein Strategic Decisions Conference Sep 23, 2021 Baader Investment Conference Sep 21, 2021 Bank of America Merrill Lynch Global Healthcare Virtual Conference Sep 15, 2021 Morgan Stanley Global Healthcare Conference Sep 13, 2021 Citi's GEMS Virtual Conference 2021 Sep 8, 2021 Second quarter results 2021 Jul 21, 2021 Basel, Switzerland Media release English (PDF 0.4 MB) [7] Deutsch (PDF 0.4 MB) [8] Français (PDF 0.4 MB) [9] Interim financial report (PDF 0.5 MB) [10] Watch the webcast [11] Read the presentation transcript [12] Download the podcast (MP3 45 MB) [13] Download the interactive presentation (PDF 4.5 MB) [14] Novartis ESG Update - July
    [Show full text]
  • Investor Presentation
    Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Q1 2021 Results Investor presentation 1 Investor Relations │ Q1 2021 Results Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “will,” “planned,” “pipeline,” “outlook,” or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding the impact of the COVID-19 pandemic on certain therapeutic areas including dermatology, ophthalmology, our breast cancer portfolio, some newly launched brands and the Sandoz retail and anti-infectives business, and on drug development operations; or regarding potential future, pending or announced transactions; regarding potential future sales or earnings of the Group or any of its divisions; or by discussions of strategy, plans, expectations or intentions; or regarding the Group’s liquidity or cash flow positions and its ability to meet its ongoing financial obligations and operational needs; or regarding our collaboration with Molecular Partners to develop, manufacture and commercialize potential medicines for the prevention and treatment of COVID- 19 and our joining of the industry-wide efforts to meet global demand for COVID-19 vaccines and therapeutics by leveraging our manufacturing capacity and capabilities to support the production of the Pfizer-BioNTech vaccine and to manufacture the mRNA and bulk drug product for the vaccine candidate CVnCoV from CureVac.
    [Show full text]
  • Amc Lapis Glob Top 20 Gen Revol
    Data as of 31.08.2021 August 2021 AMC LAPIS GLOB TOP 20 GEN REVOL PRODUCT STRATEGY FACTS AND FIGURES ISIN CH1103333931 The AMC on "LAPIS GLOBAL TOP 20 GENOMIC Currency USD REVOLUTION" is an actively managed portfolio of equities, which is based on investment Maturity Date Open End advice and recommendation by Lapis Asset NAV Date 30.08.2021 Management AG. The Lapis Global Top 20 Genomic Revolution is composed of the worldwide best-known Valor 110333393 and leading top 20 companies (gene therapy, Dividend Reinvested bioinformatics, bio-inspired computing, molecular medicine, pharmaceutical innovation) based on the FX Overlay Disabled research approach of an internationally recognized Issue Date 19.05.2021 company. All stocks are equally weighted and the NAV 110.20 certificate is rebalanced on a quarterly basis (end of January, April, July and October). Mgmt Fee (total) 1.35% Rebalancing Quarterly AuM USD 6’790’721 Components 21 Certificates 61’790 Issuer Bank Julius Baer Last Rebalancing 02.07.2021 PERFORMANCE 1 month -0.81% 52 week high 123.40 3 months 2.04% 52 week low 100.00 1 year N/A All-time high 123.40 Since inception 10.20% All-time low 100.00 YTD N/A Max draw down -14.67% Data as of 31.08.2021 August 2021 PRICE CHART MONTHLY RETURNS 2015 120 2016 115 2017 110 2018 105 2019 2020 100 8.00 13.61 -9.45 -0.81 2021 19 May 8 Jun 29 Jun 19 Jul 9 Aug 30 Aug Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec UNDERWATER EQUITY CURVE PERFORMANCE ANNUAL 0% 10% -5% 8% 2017 - 2018 - 6% 2019 - -10% 2020 - 4% 2021 10.20% 2% -15% 0% 19 May 8 Jun 29
    [Show full text]
  • French Competition Law Newsletter, October 2020
    October 2020 French Competition Law Newsletter — Highlights — The French Competition Authority fines three pharmaceutical companies for abuse of collective dominance — The French Cour de cassation upholds the Paris Court of Appeals’ judgment in the TDF abuse of dominance case — The Cour de cassation quashes the Paris Court of Appeals’ decision in the SFR/Orange case on the fixed telephony market for secondary homes for the second time The French Competition Authority fines three pharmaceutical companies for abuse of collective dominance On September 9, 2020, the French Competition of cancer. Bevacizumab was licensed to its Authority (“FCA”) fined Novartis, Roche and its parent company Roche for distribution outside subsidiary Genentech €444 million for abusing of the United States, and was granted a market their collective dominance on the market for authorization by the European Commission in AMD treatment. The FCA found that the parties 2005. In parallel, having found that Avastin could disparaged the off-label use of Roche’s Avastin also help treat age-related macular degeneration drug and spread an alarmist discourse before (“AMD”), Genentech developed and started the public authorities in order to preserve the selling ranibizumab, a specific molecule (sold dominant position and high price of Novartis’ under the name of Lucentis) that it considered Lucentis drug. more appropriate for treating AMD. Lucentis was licensed to Novartis for distribution outside of Background the United States, and was granted an EU market authorization in 2007. Novartis, already at that In the late 1990ies, US pharmaceutical company time, was one of Roche’s shareholders with a Genentech developed a revolutionary active 33,33% share of the voting rights.
    [Show full text]
  • Executive Summary 1
    Executive Summary 1 2 Novartis Pharmaceutical Production campus Executive Summary Cushman & Wakefield, Inc., as exclusive agent, is offering the Novartis Suffern Pharmaceutical Production Campus (the “Property”) for sale. This 585,000 SF multi-building complex is one of the nation’s top ten pharmaceutical manufacturing and packaging plants, with an annual solid dosage capacity in the billions. Owned and operated by Novartis, the Property has served as a vital U.S. production facility for the Company. Due to recent organizational changes and adjustments to the company’s product lines, Novartis will be vacating the facility by year end 2015. The offering provides a buyer with a rare opportunity to purchase an equipped, high-capacity pharmaceutical plant in the New York-New Jersey region. The location and size of the Campus also supports the potential redevelopment of the site for an alternative industrial use. Executive Summary 3 4 Novartis Pharmaceutical Production campus The Campus contains three interconnected buildings including a 55,000 SF office/head building which features a 7,000 SF full-service cafeteria, multiple conference/meeting rooms, and analytical laboratories. The 425,000 SF production/manufacturing building is designed as a multi-product, high volume manufacturing operation with flexible and efficient product flow; the production building contains specialized areas including granulation suites, blending rooms, encapsulation suites, analytical laboratories, inspection areas and packaging lines. The layout of the Complex facilitates the transfer of packaged products to the warehouse/shipping area; the 74,000 SF receiving and warehouse building features 90’ ceiling heights and a fully automated racking system with over 11,500 pallet positions.
    [Show full text]
  • Multi Reverse Convertible on ABB, Novartis, UBS
    Termsheet Public Offering only in: CH Yield-Enhancement Products SSPA Product Type: 1220 Multi Reverse Convertible on ABB, Novartis, UBS Autocallable - Low Strike Final Fixing Date 16/09/2022; issued in CHF; listed on SIX Swiss Exchange AG ISIN CH1117924790 - Swiss Security Number 111792479 - SIX Symbol GNHEFG Investors should read the section “Significant Risks” below as well as the section “Risk Factors” of the relevant Issuance and Offering Programme, as amended from time to time. By investing in this product (the "Product"), the Investor may put the capital that he invested in this Product at risk and, in addition, transaction costs may incur. Investors may lose some or all of their capital invested in the Product as well as transaction costs. Investors are exposed to the credit risk of the Issuer. Even though translations into other languages might be available, only the English version of the Final Terms and the relevant Issuance and Offering Programme are legally binding. For Switzerland: This Product is a derivative instrument according to Swiss law. It does not qualify as unit of a collective investment scheme pursuant to article 7 et seqq. of the Swiss Federal Act on Collective Investment Schemes ("CISA") and is therefore neither registered nor supervised by the Swiss Financial Market Supervisory Authority FINMA. Investors do not benefit from the specific investor protection provided under the CISA. This document constitutes advertising within the meaning of article 68 of the FinSA. This document is a termsheet prepared in view of the issuance of the Products and neither a prospectus within the meaning of article 35 et seqq.
    [Show full text]
  • Kansas Medical Assistance Program
    Kansas Medical Assistance Program Preferred Drug List Committee Meeting Minutes Preferred Drug List Committee Members Present: Representatives: Conrad Duncan (University of Kansas), Meeting Minutes Michael Burke, M.D., Ph.D., Chair Bruce Steinberg (Sanofi-Aventis), Debra Vickers (Sanofi- Capitol Plaza Hotel Kristen Fink, PharmD Aventis), Tom Rickman (Sanofi-Aventis), Bill Giltner Pioneer Room, Robert Haneke, PharmD (Pfizer), Kirk Becker (Pfizer), Colette Wunderlick Maner Conference Center Kenneth Mishler, PharmD (AstraZeneca), Michael Windheuser (GlaxoSmithKline), October 07, 2004 Brenda Schewe, M.D. James Lieurance (TPNA), Kim Kraenow (TPNA), Danny 10:00 A.M.-4:00 P.M. Dennis Tietze, M.D. Ottosen (Bertek Pharmaceuticals), Neal Beasly (Bristol Myers Squibb), Marguerite Enlow (Bristol Myers Squibb), SRS Staff Present: Dennis Jacobson (Sanofi-Aventis), Chris Lepore (Johnson Nialson Lee, B.S.N, M.H.A. & Johnson),Cheryl Edwards (Reliant Pharmaceuticals), Mary Obley, R.Ph. Candie Phipps (Boehringer Ingelheim), Patrick Byler Vicki Schmidt, R.Ph. (Novartis), Randy Blackwell (Biovail Pharmaceuticals), Erica Miller Mike Moratz (Merck), Dennis Bresnahan (University of Kansas Hospital – Cardiologist), James Simple (AstraZeneca),Robert Greely (Takeda), John Kiefhaber (Kansas Pharmacist Association), Joshua Lang (Novartis), Kathleen Carmody (Eli Lilly), Hal Pierce (HealthPoint), James Rider, D.O. (Geriatrics), Carol Curtis (AstraZeneca), Randy Beckner (GlaxoSmithKline), John Hawley (Reliant Pharmaceuticals), Lon Lowrey (Novartis), Scott Wilson (Andrx), Gil Preston (Watson), Matt Ackermann (Boehringer Ingelheim), Brian Michael (Novartis), Mark Ritter (Proctor & Gamble), Jason Heiderscheidt (Proctor & Gamble), Mark Hershy (Aventis), Jeffrey Fajando (Topeka Infectious Disease), Holli Hill (Sankyo Pharma), Craig Wildey (Sankyo Pharma), Barbara Boner (Novartis), Jacqueline Houston (Coventry Health Care), Elias Tawil, M.D., F.A.C.S. (Physician), Karil Bellah (Sankyo Pharma), Amy Siple, MSN, ARNP (Bio-Vail), Michael Martin (Bio-Vail) I.
    [Show full text]
  • Caring and Curing
    Caring and Curing Annual Report 2002 Novartis www.novartis.com Annual Report 2002 …molecules for medicines… Martin Klumpp, PhD, Lukas Leder, PhD, and Aline Tirat, Novartis Lead Discovery Center, Basel, Switzerland ...writing in sand... Sarvodaya Pre-School, Paluchera, Sri Lanka Contents Financial Highlights2 News in 20023 Letter from Daniel Vasella5 Amazing Patient Stories9 Division and Product Review Pharmaceuticals14 Joining Forces in the Quest for Cures22 Consumer Health29 Corporate Citizenship37 Animal Welfare46 Health, Safety and Environment49 Human Resources60 Corporate Governance Corporate Governance67 Board of Directors79 Executive Committee82 Business Unit Heads84 Financial Report Operating and Financial Review87 Equity Strategy and Share Information98 Group Consolidated Financial Statements and Notes104 Principal Companies138 Reconciliation to US GAAP140 Financial Statements of Novartis AG151 Due Dates for Reporting and Contacts157 Front cover: Svenja, a young eczema patient during an examination at the Center for Dermatology, University of Frankfurt am Main, Germany. Back cover: Svenja with her brother, Jan Patrick in the pediatric ward. Novartis Group 1 Financial Highlights Sales CHF millions Free cash flow2 CHF millions 2002 32 412 2002 4 463 2001 31 643 2001 4 073 20001 29 112 20001 3 254 Operating income CHF millions Research and development CHF millions 2002 7 887 2002 4 339 2001 7 277 2001 4 189 20001 6 727 20001 4 011 Net income CHF millions Employees at year end 2002 7 313 2002 72 877 2001 7 024 2001 71 116 20001 6
    [Show full text]
  • View the Gala Program
    Global Citizen Award presented to Professor Klaus Schwab September 23, 2010 The Plaza • New York International Advisory Board Lt Gen Brent Scowcroft, USAF (Ret.), Chairman National Security Advisor to Presidents Gerald Ford and George H. W. Bush Senator Chuck Hagel Mr. Thomas H. Glocer The Rt. Hon. Lord Robertson of Chairman, Atlantic Council of the CEO, Thompson Reuters Port Ellen United States Mr. Francisco Gonzalez Former Secretary General of NATO Mr. Frederick Kempe Chairman & CEO, BBVA Ms. Güler Sabanci President & CEO, Atlantic Council Dr. James Goodnight Chairman & Managing Director, Members: Chief Executive Officer, SAS Haci Ömer Sabanci Holding A.S. Dr. Josef Ackermann Mr. Muhtar Kent Mr. Stephen A. Schwarzman Chairman of the Management Board Chairman & CEO, Chairman, CEO & Co-Founder, & the Group Executive Committee, The Coca-Cola Company The Blackstone Group Deutsche Bank AG President Aleksander Kwasniewski Sir Martin Sorrell H.E. Shaukat Aziz Former President of Poland Group Chief Executive, WPP Group PLC Former Prime Minister of Pakistan Mr. Jean Lemierre President Jose Maria Aznar Former President, The European Bank Mr. Robert J. Stevens Former Prime Minister of Spain for Reconstruction and Development Chairman, President & CEO, Lockheed Martin Dr. Zbigniew Brzezinski Mr. Alexey A. Mordashov National Security Advisor to President CEO, Severstal Mr. Sergey A. Taruta Jimmy Carter Chairman of the Board, Mr. Bob Moritz Industrial Union of Donbass Mr. Victor L. L. Chu U.S. Chairman & Senior Partner, Chairman, First Eastern Investment PricewaterhouseCoopers Dr. Gunter Thielen Group Chairman of the Supervisory Board, Mr. Rupert Murdoch Bertelsmann AG Mr. Richard Edelman Chairman & CEO, News Corporation President & CEO, Edelman Mr.
    [Show full text]